A Gonadotrophin-releasing Hormone Agonist compared with expectant management after conservative surgery for symptomatic endometriosis

Welcome
Log-in/out; Register
Editorial Board
Contact
Disclaimer

Endometriosis explained
Monthly News
News Archive
Congress Coverage
Congress Schedule

Expert Views
Pathogenesis and theories
Diagnosis and prevention
Surgical treatment
Medical treatment
Complementary therapies
Infertility
Teenagers
Adhesions
Pain and quality of life
Physicians' Forum
Educational Tools
Image Library
Case Histories
PowerPoint Presentations
The Coping Zone
Strategies for coping
Support Groups
Endometriosis Chat Forum
Share your endometriosis
story
Resources
Job Opportunities
In the Literature
Medline
Cochrane Database
Useful Links
Search EndoZone
Glossary
Fibroids and Pregnancy



<- return | printable version | home

A Gonadotrophin-releasing Hormone Agonist compared with expectant management after conservative surgery for symptomatic endometriosis
Vercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P
First Department of Obstetrics and Gynaecology, University of Milan, Italy.

OBJECTIVE: To ascertain whether the frequency of pelvic pain recurrence is reduced and time to symptoms recurrence is prolonged in women with symptomatic endometriosis undergoing conservative surgery and post-operative hormonal therapy compared with women treated with surgery only. Pregnancy rates and time to conception in women wanting children were also evaluated.

DESIGN: A multicentre, prospective, randomised controlled study.

SETTING: Nineteen Italian academic departments and teaching hospitals specialising in reparative and reconstructive surgery.

POPULATION: A total of 269 women undergoing conservative surgery for mild to severe symptomatic endometriosis.

METHODS: After surgery the women were assigned to treatment with subcutaneous goserelin depot injections for six months or to expectant management. Dysmenorrhoea, deep dyspareunia, nonmenstrual pain and general discomfort were graded according to a verbal rating scale from 0 (absent) to 3 (severe) and the scores summed to give a total symptoms score. Only patients with at least one preoperative moderate or severe symptom were enrolled. The women were evaluated regularly for two years.

MAIN OUTCOME MEASURES: Post-operative pain recurrences (total symptoms scores > or =5), time to recurrence, pregnancy rates and time to conception in the two study groups.

RESULTS: At one- and two-year follow up visits, 14/107 (13.1%) and 19/81(23.5%) patients had moderate or severe symptoms recurrence in the goserelin group compared with, respectively, 22/103 (21.4%) and 27/74 (36.5%) in the expectant management group (P = 0.143 at 1 year and 0.082 at 2 years). Time to symptoms recurrence was significantly longer in the goserelin group according to survival analysis (Wilcoxon test, P = 0.041). Among women wanting children, few conceptions occurred in both the goserelin (8/69, 11.6%) and the expectant management group (14/76, 18.4%). There was no significant difference at survival analysis (Wilcoxon test, P = 0.427).

CONCLUSION: Post-operative treatment with goserelin significantly prolonged the pain-free interval after conservative surgery for symptomatic endometriosis and did not influence reproductive prognosis.

Source: Br J Obstet Gynaecol 1999 Jul;106(7):672-7


© www.EndometriosisZone.org